NQDI 1ASK1, MAP3K5 inhibitor CAS# 175026-96-7 |
- Melphalan
Catalog No.:BCC2403
CAS No.:148-82-3
- GRI 977143
Catalog No.:BCC2401
CAS No.:325850-81-5
- Mdivi 1
Catalog No.:BCC2402
CAS No.:338967-87-6
- DAPK Substrate Peptide
Catalog No.:BCC2400
CAS No.:386769-53-5
- Cesium chloride
Catalog No.:BCC2399
CAS No.:7647-17-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 175026-96-7 | SDF | Download SDF |
| PubChem ID | 5522952 | Appearance | Powder |
| Formula | C19H13NO4 | M.Wt | 319.31 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 10 mg/mL (31.32 mM; Need ultrasonic and warming) H2O : < 0.1 mg/mL (insoluble) | ||
| SMILES | CCOC(=O)C1=C2C3=CC=CC=C3C(=O)C4=C2C(=CC=C4)NC1=O | ||
| Standard InChIKey | UFJGFNHRMPMALC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H13NO4/c1-2-24-19(23)16-15-10-6-3-4-7-11(10)17(21)12-8-5-9-13(14(12)15)20-18(16)22/h3-9H,2H2,1H3,(H,20,22) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) (IC50 = 3 μM, Ki = 500 nM). |
NQDI 1 Dilution Calculator
NQDI 1 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1318 mL | 15.6588 mL | 31.3175 mL | 62.6351 mL | 78.2938 mL |
| 5 mM | 0.6264 mL | 3.1318 mL | 6.2635 mL | 12.527 mL | 15.6588 mL |
| 10 mM | 0.3132 mL | 1.5659 mL | 3.1318 mL | 6.2635 mL | 7.8294 mL |
| 50 mM | 0.0626 mL | 0.3132 mL | 0.6264 mL | 1.2527 mL | 1.5659 mL |
| 100 mM | 0.0313 mL | 0.1566 mL | 0.3132 mL | 0.6264 mL | 0.7829 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) (IC50 = 3 μM, Ki = 500 nM).
- Tonabersat
Catalog No.:BCC2009
CAS No.:175013-84-0
- Parishin C
Catalog No.:BCN3813
CAS No.:174972-80-6
- Parishin B
Catalog No.:BCN3812
CAS No.:174972-79-3
- Rabdoketone B
Catalog No.:BCN6598
CAS No.:174819-51-3
- 3-Amino-4-methoxybenzamide
Catalog No.:BCC8612
CAS No.:17481-27-5
- Fmoc-Hyp(Bzl)-OH
Catalog No.:BCC3255
CAS No.:174800-02-3
- Carabrone
Catalog No.:BCN1121
CAS No.:1748-81-8
- Ginsenoside Rh4
Catalog No.:BCN3503
CAS No.:174721-08-5
- 2-Amino-6-methoxybenzothiazole
Catalog No.:BCC8542
CAS No.:1747-60-0
- CH 275
Catalog No.:BCC5913
CAS No.:174688-78-9
- AN-2690
Catalog No.:BCC1360
CAS No.:174671-46-6
- Phalloidin
Catalog No.:BCC7945
CAS No.:17466-45-4
- O4I1
Catalog No.:BCC6542
CAS No.:175135-47-4
- Xanthorin
Catalog No.:BCN1122
CAS No.:17526-15-7
- Fmoc-Thr(HPO3Bzl)-OH
Catalog No.:BCC3551
CAS No.:175291-56-2
- S 18986
Catalog No.:BCC6081
CAS No.:175340-20-2
- Voreloxin
Catalog No.:BCC2044
CAS No.:175414-77-4
- Z-Phe(4-F)-OH
Catalog No.:BCC3221
CAS No.:17543-58-7
- Eriosematin A
Catalog No.:BCN3465
CAS No.:175448-02-9
- Fmoc-3-Pal-OH
Catalog No.:BCC2653
CAS No.:175453-07-3
- Fmoc-Phe(4-Cl)-OH
Catalog No.:BCC3173
CAS No.:175453-08-4
- Voreloxin Hydrochloride
Catalog No.:BCC2045
CAS No.:175519-16-1
- Longifloroside A
Catalog No.:BCN1123
CAS No.:175556-08-8
- Tapentadol Hydrochloride
Catalog No.:BCC9159
CAS No.:175591-09-0
NQDI 1, an inhibitor of ASK1 attenuates acute ischemic renal injury by modulating oxidative stress and cell death.[Pubmed:23952292]
Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):179-86.
Apoptosis signal-regulating kinase 1 (ASK1) is among the signaling events that lead to postischemic cell death. Inhibition of ASK1 pathway protected hearts from ischemic damage. The present study evaluated the renal protective effects of NQDI 1, an inhibitor of ASK1, in an animal model of acute ischemic renal failure. Male Wistar rats were subjected to right nephrectomy and clamping of left renal pedicle for 45 min, or sham operation. The administration of NQDI 1 attenuated renal dysfunction and histological changes characteristic for renal ischemia/reperfusion injury (IRI). Apoptosis of renal tissues, as detected by TUNEL staining, was also reduced together with p53 protein expression, and renal levels of MDA and SOD with NQDI 1 administration and BCL2 was up regulated. In conclusion, inhibition of ASK1 is of therapeutic potential against acute ischemic renal injury. Its protective effects are mediated via inhibition of apoptosis and oxidative stress.
NQDI-1, an inhibitor of ASK1 attenuates acute perinatal hypoxic-ischemic cerebral injury by modulating cell death.[Pubmed:27081917]
Mol Med Rep. 2016 Jun;13(6):4585-92.
Apoptosis signal-regulating kinase 1 (ASK1) is a ubiquitously expressed protein kinase, which regulates cell fate in numerous injury conditions. Therefore, ASK1 may be a promising novel therapeutic target for injury. However, the expression and distribution of ASK1 in the perinatal brain following hypoxia-ischemia (HI) remains to be elucidated. In the present study, western blotting and immunofluorescence were used to determine the expression and distribution of ASK1 and any associated downstream targets in the perinatal rat brain following HI. NQDI1, a specific inhibitor of ASK1 was intracerebroventricularly injected following neonatal rats brain insult for neuroprotection. The results revealed an increased expression of ASK1 and this expression was localized to the neurons and astrocytes, compared with the sham controls. Additionally, it was demonstrated that the ASK1/ cJun Nterminal kinases (JNK) pathway was involved in the brain damage following HI in neonatal rats. Notably, NQDI1 significantly inhibited the in vivo expression levels of ASK1, phosphorylated (p)JNK, pcJun, p53 and caspase 3. Reduced acute hypoxicischemic cerebral injury and cell apoptosis was observed following the injection of NQDI1. Collectively, NQDI-1 attenuated acute perinatal hypoxicischemic cerebral injury by inhibiting the expression of ASK1 and cell apoptosis. This may be a promising novel neuroprotective inhibitor for perinatal cerebra injury.
Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1).[Pubmed:21449566]
J Med Chem. 2011 Apr 28;54(8):2680-6.
Apoptosis signal-regulating kinase 1 (ASK1) has recently emerged as an attractive therapeutic target for the treatment of cardiac and neurodegenerative disorders. The selective inhibitors of ASK1 may become important compounds for the development of clinical agents. We have identified the ASK1 inhibitor among 3H-naphtho[1,2,3-de]quinoline-2,7-diones using receptor-based virtual screening. In vitro kinase assay revealed that ethyl 2,7-dioxo-2,7-dihydro-3H-naphtho[1,2,3-de]quinoline-1-carboxylate (NQDI-1) inhibited ASK1 with a K(i) of 500 nM. The competitive character of inhibition is demonstrated in Lineweaver-Burk plots. In our preliminary selectivity study this compound exhibited strong specific inhibitory activity toward ASK1.
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.[Pubmed:11384245]
J Med Chem. 2001 Jun 7;44(12):2004-14.
A series of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidines bearing cationic side chains were prepared from aminoanthraquinones. The perimidines were prepared from 1-aminoanthraquinone by initial condensation with urea or dimethylacetamide. A series of 2-, 4-, 8-, and 11-carboxy derivatives of the dibenzisoquinolines were prepared from aminoanthraquinonecarboxylic acids. The cationic derivatives were prepared from these via amide, amine, or methylene linkers to study the effects of side chain positioning on biological activity. Within the series of carboxamide-linked compounds, the order of increasing cytotoxicity was 8- < 4- < 2- < 11-. The 2- and 4-carboxamides showed substantial growth delays against in vivo subcutaneous colon 38 tumors in mice, but the 11-carboxamide had curative activity in this refractory model and is being investigated further.
